The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index ®.
The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.
Latest BIB News
No recent news for ProShares Ultra Nasdaq Biotechnology.
|1 month||+6.83%|| ||3 years||+92.45%|
|3 months||+22.18%|| ||5 years||+74.16%|
|1 year||+118.29%|| ||Since inception||+61.74%|
|Open day’s range||96.25 – 98.48|
|Net asset value (NAV)||97.02 (08/04/2015)|
|Average volume (3 months)||747,474|
Peer Comparisonvs. Trading-leveraged equity ETFs
|Performance 5-yr return||+74.16%||+21.46%|
|Expense Gross exp ratio||1.08%||0.89%|
|Risk 5 year sharpe ratio||1.81||--|
|Average market cap||--||--|
|Dividend / Share||--||0.21%|
|SFLA iPathÂ® Long Extended S&P 500Â® TR Index...|
|ROLA iPathÂ® Long Extended Russell 1000Â® TR ...|
|SSO ProShares Ultra S&P500|
Top 5 Sectors
Top 10 Holdings
|GILD Gilead Sciences||5.07%|